147 related articles for article (PubMed ID: 23047788)
1. Atomoxetine use during a period of FDA actions.
Du DT; Zhou EH; Goldsmith J; Nardinelli C; Hammad TA
Med Care; 2012 Nov; 50(11):987-92. PubMed ID: 23047788
[TBL] [Abstract][Full Text] [Related]
2. Acute suicidality after commencing atomoxetine.
Paxton GA; Cranswick NE
J Paediatr Child Health; 2008 Oct; 44(10):596-8. PubMed ID: 19012633
[TBL] [Abstract][Full Text] [Related]
3. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy with atomoxetine for US children and adolescents.
Bhatara VS; Aparasu RR
Ann Clin Psychiatry; 2007; 19(3):175-80. PubMed ID: 17729019
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
[TBL] [Abstract][Full Text] [Related]
6. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
Davids E; Gastpar M
Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
[TBL] [Abstract][Full Text] [Related]
7. [ADHD register: post-marketing evaluation of the benefit-risk profile of drugs and promotion of the appropriateness].
Panei P; Arcieri R
Recenti Prog Med; 2013 Jun; 104(6):254-61. PubMed ID: 23801229
[TBL] [Abstract][Full Text] [Related]
8. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
[TBL] [Abstract][Full Text] [Related]
9. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
10. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
[TBL] [Abstract][Full Text] [Related]
11. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
Adler LA; Sutton VK; Moore RJ; Dietrich AP; Reimherr FW; Sangal RB; Saylor KE; Secnik K; Kelsey DK; Allen AJ
J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824
[TBL] [Abstract][Full Text] [Related]
12. Decreased use of clonidine following treatment with atomoxetine in children with ADHD.
Johnston JA; Ye W; Van Brunt DL; Pohl G; Sumner CR
J Clin Psychopharmacol; 2006 Aug; 26(4):389-95. PubMed ID: 16855457
[TBL] [Abstract][Full Text] [Related]
13. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
14. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
Sasané R; Hodgkins P; Meijer W
Curr Med Res Opin; 2010 Nov; 26(11):2565-74. PubMed ID: 20863165
[TBL] [Abstract][Full Text] [Related]
15. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
[TBL] [Abstract][Full Text] [Related]
16. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine.
Wernicke JF; Holdridge KC; Jin L; Edison T; Zhang S; Bangs ME; Allen AJ; Ball S; Dunn D
Dev Med Child Neurol; 2007 Jul; 49(7):498-502. PubMed ID: 17593120
[TBL] [Abstract][Full Text] [Related]
17. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder.
Newcorn JH; Michelson D; Kratochvil CJ; Allen AJ; Ruff DD; Moore RJ;
Pediatrics; 2006 Dec; 118(6):e1701-6. PubMed ID: 17101710
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
[TBL] [Abstract][Full Text] [Related]
19. Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.
Kornfield R; Watson S; Higashi AS; Conti RM; Dusetzina SB; Garfield CF; Dorsey ER; Huskamp HA; Alexander GC
Psychiatr Serv; 2013 Apr; 64(4):339-46. PubMed ID: 23318985
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine treatment of attention-deficit/hyperactivity disorder.
Eiland LS; Guest AL
Ann Pharmacother; 2004 Jan; 38(1):86-90. PubMed ID: 14742801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
